The modern view of treatment of allergic rhinitis and it’s combination with bronchial asthma

In recent years, there has been a significant increase in the prevalence of diseases of the nose and paranasal sinuses. Inflammatory diseases of the mucous membrane nasal cavities (rhinitis) are most commonly characterized as a syndrome in which the patient experiences some combination of persistent nasal symptoms, including rhinorrhea, sneezing, nasal congestion, itching and burning in the nasal cavity. Among the chronic forms of rhinitis, allergic rhinitis occupies a large place along with vasomotor, infectious, hypertrophic, catarrhal and atrophic rhinitis. Allergic rhinitis is a significant social and medico-economic problem, since it significantly reduces the quality of life of patients and requires significant treatment costs. This nosology is found in the practice of doctors of all specialties, however, the correct diagnosis and the appointment of adequate therapy can take many months and years. Currently, the concept of “common airways” is widely discussed, which demonstrates the close relationship between allergic rhinitis and bronchial asthma and proves that the inflammatory response can be supported and enhanced by interrelated mechanisms. Therefore, patients with allergic rhinitis should be examined for the presence of bronchial asthma. In turn, patients with bronchial asthma need to diagnose allergic rhinitis, and treatment should be aimed at suppressing allergic inflammation in both the upper and lower respiratory tract. This article discusses modern diagnostic and therapeutic approaches to patients with these diseases, which make it possible to efficiently and timely identify allergic rhinitis and initiate appropriate adequate treatment. The article also discusses the feasibility of using combined therapy with levocetirizine and montelukast in the above nosologies.

1. Wise S.K., Lin S.Y., Toskala E., Orlandi R.R., Akdis C.A., Alt J.A. et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. doi: 10.1002/alr.22073.

2. Kurbacheva O.M., Polner S.A., Smirnov D.S. Modern approach to the treatment of respiratory allergy. Bolezni organov dykhaniya. Consilium Medicum = Respiratory Organs Diseases. Consilium Medicum. 2016;(1):28–35. (In Russ.) Available at: https://elibrary.ru/item.asp?id=27593498.

3. Koberlein J., Kothe A.C., Sieber J., Mosges R. Determining factors of patient compliance to treatment in allergic rhinitis. Asian Pac J Allergy Immunol. 2013;31(2):148–156. doi: 10.12932/AP0264.31.2.2013.

4. Ilyina N.I. Allergy is a multidisciplinary problem. Only at the intersection of specialties can you achieve success in its treatment. Effektivnaya farmakoterapiya. Allergologiya i immunologiya = Effective Pharmacotherapy. Allergology and Immunology. 2012;(2):2–5. (In Russ.) Available at: https://umedp.ru/upload/iblock/2b7/1.pdf.

5. Gushchin I.S., Kurbacheva O.M. Allergy and allergen-specific immunotherapy. Moscow: Farmarus Print; 2010. 228 p. (In Russ.).

6. Aynaci S., Cakli H., Cingi E. Efficacy of long-term sublingual-oral immunotherapy in allergic rhinitis. ACTA Otorhinolaryngol Ital. 2005;25(4):214–219. Available at: https://pubmed.ncbi.nlm.nih.gov/16482978.

7. Khaitov R.M., Il’ina N.I. (eds.) Allergology and immunology. National leadership. Moscow: Geotar-Media; 2009. (In Russ.) Available at: https://rosmedlib.ru/book/ISBN9785970409039.html.

8. Ilyina N.I., Kurbacheva O.M., Pavlova K.S., Polner S.A. Federal Clinical Recommendations. Allergic Rhinitis. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2018;15(4):43–53. (In Russ.) Available at: https://elibrary.ru/item.asp?id=36285923.

9. Nazarova E.V., Ilyina N.I. Allergic rhinitis: current approaches to diagnosis and treatment. Effektivnaya farmakoterapiya. Allergologiya i immunologiya = Effective Pharmacotherapy. Allergology and Immunology. 2012;(2):18–24. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21405537.

10. Brozek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2017 revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi: 10.1016/j.jaci.2017.03.050.

11. Khaitov R.M., Ilyina N.I., Kurbacheva O.M., Pavlova K.S. Traditions, sucsess and innovations in modern allergology. Fiziologiya i patologiya immunnoy sistemy. Immunofarmakogenomika = Physiology and pathology of the immune system. 2010;14(1):3–14. (In Russ.) Available at: https://elibrary.ru/item.asp?id=23709675.

12. Gushchin I.S. Allergic inflammation and its pharmacological control. Moscow: Farmarus Print; 1998. 252 p. (In Russ.).

13. Khaitov M.R., Namazova-Baranova L.S., Ilyina N.I., Kurbacheva O.M., Bachert C., Hellings P.W. et al. 2019 ARIA: Care pathways for allergic rhinitis in russia. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2020;17(1):7–22. (In Russ.) Available at: https://elibrary.ru/item.asp?id=42610680.

14. Holgate S.T. Experimental models in asthma. Clin Exp Allergy. 1999;29(Suppl. 3):82–86. doi: 10.1046/j.1365-2222.1999.0290s3082.x.

15. Simons F.E. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma? Clin Exp Allergy. 1999;29(3 Suppl.):98–104. doi: 10.1046/j.1365-2222.1999.0290s3098.x.

16. Wood Baker R., Holgate S.T. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol. 1993;91(5):1005–1014. doi: 10.1016/0091-6749(93)90213-y.

17. Roquet A., Dahlén B., Kumlin M., Ihre E., Anstrén G., Binks S., Dahlén S.E. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 1997;155(6):1856–1863. doi: 10.1164/ajrccm.155.6.9196086.

18. Van Ganse E., Kaufman L., Derde M.P., Yernault J.C., Delaunois L., Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J. 1997;10(10):2216–2224. doi: 10.1183/09031936.97.10102216.

19. Busse W.W., Middleton E., Storms W., Dockhorn R.J., Chu T.J., Grossman J. et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med. 1996;153(1):122–127. doi: 10.1164/ajrccm.153.1.8542104.

20. Gould C.A.L., Ollier S., Aurich R., Davies R.J. A study of the clinical efficacy of azelastine in patients with extrinsic asthma, and its effect on airway responsiveness. Br J Clin Pharmacol. 1988;26(5):515–525. doi: 10.1111/j.1365-2125.1988.tb05291.x.

21. Bousquet J., Emonot A., Germouty J., Molina C., Montané F., Perrin-Fayolle M. et al. Double-blind multicenter study of cetirizine in grass-pollen-induced asthma. Ann Allergy. 1990;65(6):504–508. Available at: https://pubmed.ncbi.nlm.nih.gov/1979473.

22. Ekström T., Osterman K., Zetterström O. Lack of effect of loratadine on moderate to severe asthma. Ann Allergy Asthma Immunol. 1995;75(3):287–289. Available at: https://pubmed.ncbi.nlm.nih.gov/7552933.

23. Spector S.L., Nicodemus C.F., Corren J., Schanker H.M., Rachelefsky G.S., Katz R.M., Siegel S.C. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. J Allergy Clin Immunol. 1995;96(2):174–181. doi: 10.1016/s0091-6749(95)70005-6.

24. Baena-Cagnani C.E., Berger W.E., DuBuske L.M., Gurné S.E., Stryszak P., Lorber R., Danzig M. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003;130(4):307–313. doi: 10.1159/000070218.

25. Simons F.E. Allergic rhinobronchitis. the asthma/allergic rhinitis link. J Allergy Clin Immunol. 1999;104(3 Pt. 1):534–540. doi: 10.1016/s0091-6749(99)70320-9.

26. Corren J., Harris A.G., Aaronson D., Beaucher W., Berkowitz R., Bronsky E. et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997;100(6 Pt. 7):781–788. doi: 10.1016/s0091-6749(97)70274-4.

27. Grant J.A., Nicodemus C.F., Findlay S.R., Glovsky M.M., Grossman J., Kaiser H. et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo controlled trial. J Allergy Clin Immunol. 1995;95(5 Pt. 1):923–932. doi: 10.1016/s0091-6749(95)70090-0.

28. Shamsi Z., Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol. 2000;15(S1):3–30. doi: 10.1002/1099-1077(200010)15:1+3.0.CO;2-S.

29. Reicin A., White R., Weinstein S., Finn J.A., Nguyen H., Peszek I. et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 2000;160(16):2481–2488. doi: 10.1001/archinte.160.16.2481.

30. Simons F.E. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–2217. doi: 10.1056/NEJMra033121.

31. Ciebiada M., Górska-Ciebiada M., DuBuske L.M., Górski P. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(5):664–671. doi: 10.1016/S1081-1206(10)61098-8.

32. Panchal S., Patil S., Barkate H. Evaluation of efficacy and safety of montelukast and levocetirizine FDC tablet compared to montelukast and levocetirizine tablet in patients with seasonal allergic rhinitis: a randomized, double blind, multicentre, phase III trial. Int J Otorhinolaryngol Head Neck Surg. 2020;7(1):83. doi: 10.18203/issn.2454-5929.ijohns20205625.